Breeding and brewing quality of the Canadian malting barley variety 'CDC Goldstar' lacking lipoxygenase-1.

Various types of malt quality profiles have been investigated to benefit the North American brewing industry. Herein, we report the development and brewing quality of the hulled, two-row malting barley ( L.) variety 'CDC Goldstar' lacking lipoxygenase-1 (LOX-1-less). This new variety offers a novel malt type for the improvement of beer flavor stability. The agronomic performance of 'CDC Goldstar' was tested in the Western Cooperative Two Row Barley Registration Trials during 2013-2014. In addition to high lodging tolerance, the new variety showed 6% higher yield than the current leading variety 'CDC Copeland'. The malt quality of 'CDC Goldstar' showed higher diastatic power and lower wort β-glucan content than 'CDC Copeland' and controllable proteolytic modification (soluble nitrogen and Kolbach Index). Pilot- (100 L) and commercial-scale (5,000 L) brewing trials were conducted using 'CDC PlatinumStar', another LOX-1-less variety with a low enzymatic profile, as the control variety. Absence of the LOX-1 trait from 'CDC Goldstar' maintained -2-nonenal levels in aged beers as low as those in other LOX-1-less varieties without affecting major beer parameters, such as ester and aldehyde content or foam stability. The newly developed 'CDC Goldstar' malting barley provides added value for the beer industry and consumers.